Citi On The Impact Of Biosimilars And Losing $360 Billion In Revenues By: Benzinga via Benzinga February 09, 2015 at 11:13 AM EST Citi analyst Andrew Baum released research notes on several pharmaceutical companies Monday. Baum’s overarching theme was about ... Read More >> Related Stocks: Actavis Plc Journey Medical Corp Pfizer